I4V-MC-JAJJ: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to
Phase 3 – large-scale trial before approval
Conditions:
Diabetes Mellitus
Type 1
Sponsor: Eli Lilly & Co.
trial.available_in:
БГ
Overview
Trial status: Authorised
Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes [Time Frame: Baseline up to approximately 5 years]
Who can participate
Age group: 0-17 years, 18-64 years
Gender: Female, Male
Target enrollment: 97 participants
БГ